Chongqing Boteng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company") held the 30th temporary meeting of the 5th Board of Directors on February 26, 2025, and approved the proposal to invest in the Songhe Capital Cell and Gene Industry Fund. The Company intends to contribute no more than 50 million RMB of its own funds to participate in the investment in the Shenzhen Songhe Cell and Gene Industry Private Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as "the Fund"). For specific details, please refer to the announcement disclosed by the Company on the same day on the Giant Tide Information Network (Announcement No.: 2025-004).
Recently, the Company received a notification from the fund manager, Shenzhen Songhe Capital Management Co., Ltd., that the Fund has completed registration with the Asset Management Association of China in accordance with the Securities Investment Fund Law and the Interim Measures for the Supervision and Administration of Private Investment Funds, and has completed the relevant industrial and commercial change registration procedures. The specific registration information is as follows: